BTAI BioXcel Therapeutics | $2.53
-4.2% | 3/19/2025 | | Initiated Coverage | $65.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025 |
TELO Telomir Pharmaceuticals | $1.40
+0.7% | 2/21/2025 | | Initiated Coverage | $15.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/21/2025 |
CRDL Cardiol Therapeutics | $1.07
+1.9% | 1/28/2025 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025 |
INMB INmune Bio | $2.08
-2.8% | 1/28/2025 | | Initiated Coverage | $23.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025 |
PYPD PolyPid | $3.50
+1.2% | 1/28/2025 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025 |
TLPH Talphera | $0.95
+0.9% | 1/28/2025 | | Initiated Coverage | $4.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025 |
ATRA Atara Biotherapeutics | $14.41
-0.5% | 12/20/2024 | | Initiated Coverage | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
HURA TuHURA Biosciences | $2.60
-0.4% | 12/19/2024 | | Initiated Coverage | $11.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
FBLG FibroBiologics | $0.55
+1.7% | 12/12/2024 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of FibroBiologics (NASDAQ:FBLG) on 12/12/2024 |
THAR Tharimmune | $2.91
-4.6% | 12/6/2024 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
ACHV Achieve Life Sciences | $3.15
-1.3% | 11/14/2024 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
EPRX Eupraxia Pharmaceuticals | $5.85
-2.5% | 11/14/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
OMER Omeros | $4.58
+8.5% | 11/14/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
RMTI Rockwell Medical | $1.22
+0.8% | 11/14/2024 | | Initiated Coverage | $5.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
BCAX Bicara Therapeutics | $17.04
+2.0% | 11/5/2024 | | Initiated Coverage | $48.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
QNCX Quince Therapeutics | $1.65
+0.6% | 10/29/2024 | | Initiated Coverage | $11.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
ANRO Alto Neuroscience | $6.87
+55.8% | 10/23/2024 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024 |
MNPR Monopar Therapeutics | $99.39
+2.2% | 10/11/2024 | | Initiated Coverage | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024 |
KYTX Kyverna Therapeutics | $5.52
-9.2% | 10/9/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
NKTX Nkarta | $2.13
-2.7% | 10/9/2024 | | Initiated Coverage | $14.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
MIRA MIRA Pharmaceuticals | $1.35
+0.7% | 9/30/2024 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
BMEA Biomea Fusion | $2.15
+0.9% | 9/26/2024 | | Upgrade | $18.00 | Neutral ➝ Buy | 00.00% | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 |
EBS Emergent Biosolutions | $9.12
-0.8% | 9/13/2024 | | Reiterated Rating | $16.00 ➝ $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 9/13/2024 |
ATHA Athira Pharma | $4.14
-0.5% | 9/4/2024 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 9/4/2024 |
PASG Passage Bio | $7.95
-1.2% | 9/3/2024 | | Initiated Coverage | $140.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024 |
CRMD CorMedix | $11.34
+2.6% | 8/26/2024 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024 |
DERM Journey Medical | $7.33
+0.4% | 8/22/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024 |
EBS Emergent Biosolutions | $9.12
-0.8% | 8/22/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 8/22/2024 |
MIST Milestone Pharmaceuticals | $2.11
-3.2% | 8/22/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024 |
ATHA Athira Pharma | $4.14
-0.5% | 8/19/2024 | | Initiated Coverage | $220.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 8/19/2024 |
IPSC Century Therapeutics | $0.51
+3.2% | 8/8/2024 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024 |
SAVA Cassava Sciences | $3.63
+5.8% | 8/8/2024 | | Reiterated Rating | $107.00 ➝ $107.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:SAVA) on 8/8/2024 |
CRSP CRISPR Therapeutics | $67.74
-7.0% | 8/2/2024 | | Initiated Coverage | $90.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024 |
ANVS Annovis Bio | $2.22
-0.7% | 7/2/2024 | | Reiterated Rating | $67.00 ➝ $67.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $1.55
+8.4% | 7/2/2024 | | Reiterated Rating | $14.00 ➝ $14.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
LPTX Leap Therapeutics | $0.53
-26.9% | 6/28/2024 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Leap Therapeutics (NASDAQ:LPTX) on 6/28/2024 |
MURA Mural Oncology | $2.08
+0.5% | 6/28/2024 | | Initiated Coverage | $15.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Mural Oncology (NASDAQ:MURA) on 6/28/2024 |
NKTR Nektar Therapeutics | $60.55
+0.1% | 6/28/2024 | | Initiated Coverage | $30.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
SANA Sana Biotechnology | $3.96
-0.3% | 6/26/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
ANRO Alto Neuroscience | $6.87
+55.8% | 6/21/2024 | | Initiated Coverage | $43.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
|
COYA Coya Therapeutics | $6.10
+3.9% | 6/13/2024 | | Initiated Coverage | $18.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
HRTX Heron Therapeutics | $1.32
+1.5% | 6/13/2024 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
MNKD MannKind | $5.76
+4.9% | 6/13/2024 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
RANI Rani Therapeutics | $0.51
| 6/13/2024 | | Initiated Coverage | $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
SCLX Scilex | $15.78
-9.0% | 6/13/2024 | | Initiated Coverage | $455.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
TRVI Trevi Therapeutics | $9.88
+3.3% | 6/13/2024 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
AVDL Avadel Pharmaceuticals | $15.01
+0.5% | 6/12/2024 | | Initiated Coverage | $27.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 6/12/2024 |
ANVS Annovis Bio | $2.22
-0.7% | 6/4/2024 | | Initiated Coverage | $67.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Cos | $6.69
+2.1% | 8/10/2017 | | Reiterated Rating | $17.00 | Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $11.34
+2.6% | 8/10/2017 | | Lower Price Target | $25.00 ➝ $15.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |
GEVO Gevo | $2.14
+5.4% | 8/9/2017 | | Reiterated Rating | $240.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017 |
VERU Veru | $3.80
-1.6% | 7/26/2017 | | Initiated Coverage | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017 |
PLUG Plug Power | $3.81
+34.6% | 7/24/2017 | | Reiterated Rating | $4.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017 |
CAPR Capricor Therapeutics | $7.36
-7.7% | 7/22/2017 | | Reiterated Rating | $2.15 | Buy | 00.00% | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017 |
BYSI BeyondSpring | $1.75
+1.2% | 7/14/2017 | | Boost Price Target | $43.00 ➝ $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017 |
FBIO Fortress Biotech | $2.75
-1.8% | 7/11/2017 | | Initiated Coverage | $165.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017 |
AQMS Aqua Metals | $6.99
-8.6% | 7/2/2017 | | Initiated Coverage | $5,000.00 ➝ $5,000.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 7/2/2017 |
AQMS Aqua Metals | $6.99
-8.6% | 6/22/2017 | | Initiated Coverage | $5,000.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 6/22/2017 |
EYPT Eyepoint Pharmaceuticals | $13.73
+1.7% | 5/30/2017 | | Initiated Coverage | $800.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 5/30/2017 |
PLX Protalix BioTherapeutics | $2.43
+3.8% | 5/23/2017 | | Reiterated Rating | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 5/23/2017 |
ACAD ACADIA Pharmaceuticals | $21.80
+2.0% | 5/22/2017 | | Reiterated Rating | $60.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) on 5/22/2017 |
BHC Bausch Health Cos | $6.69
+2.1% | 5/19/2017 | | Reiterated Rating | $17.00 | Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/19/2017 |
MGIC Magic Software Enterprises | $20.68
+1.4% | 5/17/2017 | | Reiterated Rating | $9.00 ➝ $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 5/17/2017 |
IOVA Iovance Biotherapeutics | $2.34
+4.0% | 5/10/2017 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/10/2017 |
CRMD CorMedix | $11.34
+2.6% | 5/5/2017 | | Lower Price Target | $30.00 ➝ $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 5/5/2017 |
AMSC American Superconductor | $59.30
+0.1% | 4/28/2017 | | Reiterated Rating | $10.00 ➝ $7.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/28/2017 |
B Barrick Mining | C$33.94
+0.0% | 4/24/2017 | | Boost Price Target | C$4.25 ➝ C$4.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 4/24/2017 |
PLX Protalix BioTherapeutics | $2.43
+3.8% | 4/17/2017 | | Reiterated Rating | $40.00 ➝ $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLX Protalix BioTherapeutics | $2.43
+3.8% | 4/17/2017 | | Boost Price Target | $40.00 ➝ $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLUG Plug Power | $3.81
+34.6% | 4/6/2017 | | Boost Price Target | $3.00 ➝ $4.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 4/6/2017 |
BYSI BeyondSpring | $1.75
+1.2% | 4/4/2017 | | Initiated Coverage | $43.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 4/4/2017 |
CYTK Cytokinetics | $56.97
+1.2% | 3/23/2017 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/23/2017 |
HROW Harrow | $45.43
-4.8% | 3/22/2017 | | Reiterated Rating | $5.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 3/22/2017 |
CYTK Cytokinetics | $56.97
+1.2% | 3/8/2017 | | Initiated Coverage | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/8/2017 |
BHC Bausch Health Cos | $6.69
+2.1% | 3/6/2017 | | Lower Price Target | $23.00 ➝ $17.00 | Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/6/2017 |
MGIC Magic Software Enterprises | $20.68
+1.4% | 3/6/2017 | | Reiterated Rating | $8.00 ➝ $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 3/6/2017 |
QRHC Quest Resource | $1.56
| 3/6/2017 | | Initiated Coverage | $5.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Quest Resource (NASDAQ:QRHC) on 3/6/2017 |
BHC Bausch Health Cos | $6.69
+2.1% | 2/27/2017 | | Reiterated Rating | $23.00 ➝ $17.00 | Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/27/2017 |
BLRX BioLineRx | $4.00
+2.6% | 2/13/2017 | | Initiated Coverage | $120.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BioLineRx (NASDAQ:BLRX) on 2/13/2017 |
CAPR Capricor Therapeutics | $7.36
-7.7% | 2/13/2017 | | Initiated Coverage | $14.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 2/13/2017 |
ABEO Abeona Therapeutics | $5.41
+1.7% | 2/7/2017 | | Reiterated Rating | $425.00 ➝ $500.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 2/7/2017 |
BHC Bausch Health Cos | $6.69
+2.1% | 1/31/2017 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 1/31/2017 |
ASM Avino Silver & Gold Mines | C$5.45
+4.8% | 1/24/2017 | | Boost Price Target | C$3.50 ➝ C$4.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
CHEK Check-Cap | $2.27
-5.0% | 1/19/2017 | | Initiated Coverage | $1,440.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Check-Cap (NASDAQ:CHEK) on 1/19/2017 |
NAGE Niagen Bioscience | $6.93
-6.1% | 1/3/2017 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Niagen Bioscience (NASDAQ:NAGE) on 1/3/2017 |
PLUG Plug Power | $3.81
+34.6% | 12/6/2016 | | Initiated Coverage | $3.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 12/6/2016 |
B Barrick Mining | C$33.94
+0.0% | 11/28/2016 | | Boost Price Target | C$4.00 ➝ C$4.25 | Buy | 00.00% | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 11/28/2016 |
HROW Harrow | $45.43
-4.8% | 11/28/2016 | | Initiated Coverage | $5.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 11/28/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 11/10/2016 | | Downgrade | $81.00 ➝ $23.00 | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 11/10/2016 |
DRRX DURECT | $1.91
| 9/27/2016 | | Reiterated Rating | $40.00 ➝ $35.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 9/27/2016 |
|
AYTU Aytu BioPharma | $1.90
-3.6% | 9/26/2016 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Aytu BioPharma (NASDAQ:AYTU) on 9/26/2016 |
CLNE Clean Energy Fuels | $2.73
+5.0% | 9/23/2016 | | Reiterated Rating | $5.00 ➝ $6.30 | Buy | 00.00% | View details for Rodman & Renshaw rating of Clean Energy Fuels (NASDAQ:CLNE) on 9/23/2016 |
HL Hecla Mining | $11.89
-1.4% | 9/6/2016 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Hecla Mining (NYSE:HL) on 9/6/2016 |
DRIO DarioHealth | $16.35
-5.3% | 8/22/2016 | | Reiterated Rating | $240.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 8/22/2016 |
ABEO Abeona Therapeutics | $5.41
+1.7% | 8/21/2016 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/21/2016 |
ORMP Oramed Pharmaceuticals | $2.44
-2.8% | 8/21/2016 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 8/21/2016 |
EFOI Energy Focus | $2.59
| 8/15/2016 | | Boost Price Target | $280.00 ➝ $560.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/15/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 8/9/2016 | | Lower Price Target | $90.00 ➝ $81.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/9/2016 |
ABEO Abeona Therapeutics | $5.41
+1.7% | 8/5/2016 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/5/2016 |
DRRX DURECT | $1.91
| 8/3/2016 | | Reiterated Rating | $40.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 8/3/2016 |
EKSO Ekso Bionics | $5.60
+5.3% | 7/31/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 7/31/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 7/28/2016 | | Reiterated Rating | $90.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/28/2016 |
F Ford Motor | $12.66
+3.6% | 7/18/2016 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of Ford Motor (NYSE:F) on 7/18/2016 |
KURA Kura Oncology | $9.57
+4.7% | 7/18/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 7/18/2016 |
OESX Orion Energy Systems | $8.26
+0.4% | 7/18/2016 | | Initiated Coverage | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Orion Energy Systems (NASDAQ:OESX) on 7/18/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 7/17/2016 | | Reiterated Rating | $90.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/17/2016 |
PLX Protalix BioTherapeutics | $2.43
+3.8% | 7/11/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 7/11/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 7/6/2016 | | Reiterated Rating | $90.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/6/2016 |
DRRX DURECT | $1.91
| 7/6/2016 | | Reiterated Rating | $40.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 7/6/2016 |
CBIO Crescent Biopharma | $11.72
-2.6% | 6/30/2016 | | Initiated Coverage | $5,250.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Crescent Biopharma (NASDAQ:CBIO) on 6/30/2016 |
INO Inovio Pharmaceuticals | $2.43
-1.2% | 6/21/2016 | | Reiterated Rating | $2,448.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 6/21/2016 |
WPRT Westport Fuel Systems | $2.33
+2.6% | 6/20/2016 | | Initiated Coverage | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Westport Fuel Systems (NASDAQ:WPRT) on 6/20/2016 |
DRIO DarioHealth | $16.35
-5.3% | 5/24/2016 | | Reiterated Rating | $240.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/24/2016 |
KURA Kura Oncology | $9.57
+4.7% | 5/24/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 5/24/2016 |
ABEO Abeona Therapeutics | $5.41
+1.7% | 5/18/2016 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 5/18/2016 |
DRRX DURECT | $1.91
| 5/13/2016 | | Reiterated Rating | $40.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 5/13/2016 |
ORMP Oramed Pharmaceuticals | $2.44
-2.8% | 5/13/2016 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 5/13/2016 |
MBOT Microbot Medical | $3.07
-3.2% | 5/10/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 5/10/2016 |
DRIO DarioHealth | $16.35
-5.3% | 5/9/2016 | | Initiated Coverage | $240.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/9/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 5/3/2016 | | Lower Price Target | $105.00 ➝ $102.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/3/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 4/26/2016 | | Reiterated Rating | $105.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/26/2016 |
DRRX DURECT | $1.91
| 4/25/2016 | | Initiated Coverage | $40.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 4/25/2016 |
ABEO Abeona Therapeutics | $5.41
+1.7% | 4/20/2016 | | Reiterated Rating | $425.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 4/20/2016 |
MBOT Microbot Medical | $3.07
-3.2% | 4/20/2016 | | Initiated Coverage | $18.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 4/20/2016 |
AG First Majestic Silver | $12.11
+0.4% | 4/15/2016 | | Boost Price Target | $6.00 ➝ $8.75 | Buy | 00.00% | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 4/15/2016 |
SMLR Semler Scientific | $30.56
-2.6% | 4/15/2016 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Semler Scientific (NASDAQ:SMLR) on 4/15/2016 |
EXK Endeavour Silver | $7.70
+0.9% | 4/12/2016 | | Boost Price Target | $2.50 ➝ $3.40 | Buy | 00.00% | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 4/12/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 4/11/2016 | | Lower Price Target | $118.00 ➝ $105.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/11/2016 |
INO Inovio Pharmaceuticals | $2.43
-1.2% | 4/9/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 4/9/2016 |
EKSO Ekso Bionics | $5.60
+5.3% | 4/5/2016 | | Reiterated Rating | $4,725.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 4/5/2016 |
KURA Kura Oncology | $9.57
+4.7% | 4/4/2016 | | Initiated Coverage | $52,500.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 4/4/2016 |
PLX Protalix BioTherapeutics | $2.43
+3.8% | 4/4/2016 | | Initiated Coverage | $35.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/4/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 4/3/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/3/2016 |
AMSC American Superconductor | $59.30
+0.1% | 4/1/2016 | | Reiterated Rating | | Neutral | 00.00% | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/1/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 3/28/2016 | | Reiterated Rating | $118.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/28/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 3/22/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/22/2016 |
NNDM Nano Dimension | $1.60
+1.9% | 3/21/2016 | | Initiated Coverage | $700.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Nano Dimension (NASDAQ:NNDM) on 3/21/2016 |
INO Inovio Pharmaceuticals | $2.43
-1.2% | 3/20/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 3/20/2016 |
CRMD CorMedix | $11.34
+2.6% | 3/17/2016 | | Boost Price Target | $32.50 ➝ $37.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 3/17/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 3/16/2016 | | Lower Price Target | $150.00 ➝ $118.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/16/2016 |
|
MUX McEwen | $17.38
+5.8% | 3/14/2016 | | Boost Price Target | $13.00 ➝ $24.00 | | 00.00% | View details for Rodman & Renshaw rating of McEwen (NYSE:MUX) on 3/14/2016 |
INSG Inseego | $17.28
+4.7% | 3/7/2016 | | Lower Price Target | $60.00 ➝ $30.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Inseego (NASDAQ:INSG) on 3/7/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 3/2/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/2/2016 |
AG First Majestic Silver | $12.11
+0.4% | 2/29/2016 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 2/29/2016 |
EXK Endeavour Silver | $7.70
+0.9% | 2/29/2016 | | Initiated Coverage | $2.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 2/29/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 2/23/2016 | | Reiterated Rating | $150.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/23/2016 |
RDCM Radcom | $13.82
-0.9% | 2/18/2016 | | Boost Price Target | $12.00 ➝ $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Radcom (NASDAQ:RDCM) on 2/18/2016 |
BHC Bausch Health Cos | $6.69
+2.1% | 2/16/2016 | | Initiated Coverage | $150.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/16/2016 |
BCRX BioCryst Pharmaceuticals | $7.15
-2.5% | 2/9/2016 | | Lower Price Target | $24.00 ➝ $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 2/9/2016 |
INO Inovio Pharmaceuticals | $2.43
-1.2% | 1/29/2016 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 1/29/2016 |
IPWR Ideal Power | $5.42
+2.7% | 1/26/2016 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Ideal Power (NASDAQ:IPWR) on 1/26/2016 |
AMSC American Superconductor | $59.30
+0.1% | 1/13/2016 | | Initiated Coverage | $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 1/13/2016 |
ORMP Oramed Pharmaceuticals | $2.44
-2.8% | 1/10/2016 | | Reiterated Rating | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 1/10/2016 |
MVIS Microvision | $1.42
+6.0% | 12/17/2015 | | Initiated Coverage | $3.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of Microvision (NASDAQ:MVIS) on 12/17/2015 |
CRMD CorMedix | $11.34
+2.6% | 12/16/2015 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 12/16/2015 |
VUZI Vuzix | $3.89
+2.6% | 12/10/2015 | | Initiated Coverage | $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Vuzix (NASDAQ:VUZI) on 12/10/2015 |
CRMD CorMedix | $11.34
+2.6% | 11/12/2015 | | Initiated Coverage | $32.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 11/12/2015 |
BLDP Ballard Power Systems | $3.53
+23.0% | 10/5/2015 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 10/5/2015 |
ORMP Oramed Pharmaceuticals | $2.44
-2.8% | 10/1/2015 | | Initiated Coverage | $24.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 10/1/2015 |
BLDP Ballard Power Systems | $3.53
+23.0% | 8/20/2015 | | Initiated Coverage | $2.50 | Buy | 00.00% | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 8/20/2015 |
GEVO Gevo | $2.14
+5.4% | 8/19/2015 | | Initiated Coverage | $100.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/19/2015 |
EFOI Energy Focus | $2.59
| 8/7/2015 | | Initiated Coverage | $630.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/7/2015 |
BLDP Ballard Power Systems | $3.53
+23.0% | 7/14/2015 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 7/14/2015 |
EFOI Energy Focus | $2.59
| 6/25/2015 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 6/25/2015 |
CPRX Catalyst Pharmaceuticals | $20.84
| 8/27/2012 | | Upgrade | $3.70 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) on 8/27/2012 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 7/31/2012 | | Reiterated Rating | $22.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/31/2012 |
CYTK Cytokinetics | $56.97
+1.2% | 7/31/2012 | | Reiterated Rating | $2.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 7/31/2012 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 7/27/2012 | | Boost Price Target | $38.00 ➝ $39.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/27/2012 |
AMGN Amgen | $297.89
+0.2% | 7/23/2012 | | Boost Price Target | $73.00 ➝ $89.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 7/23/2012 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 7/16/2012 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/16/2012 |
ALGT Allegiant Travel | $62.79
+4.8% | 7/13/2012 | | Boost Price Target | $72.00 ➝ $79.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 7/13/2012 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 7/5/2012 | | Reiterated Rating | $38.00 | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/5/2012 |
ASMB Assembly Biosciences | $23.32
-1.6% | 6/26/2012 | | Lower Price Target | $132.00 | | 00.00% | View details for Rodman & Renshaw rating of Assembly Biosciences (NASDAQ:ASMB) on 6/26/2012 |
AMGN Amgen | $297.89
+0.2% | 6/21/2012 | | Boost Price Target | $57.00 ➝ $73.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 6/21/2012 |
DCO Ducommun | $94.78
+0.6% | 5/24/2012 | | Initiated Coverage | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Ducommun (NYSE:DCO) on 5/24/2012 |
POWL Powell Industries | $304.06
-1.1% | 5/10/2012 | | Upgrade | $43.00 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 5/10/2012 |
NPO Enpro | $228.50
+0.1% | 5/4/2012 | | Boost Price Target | $47.00 ➝ $50.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 5/4/2012 |
RMTI Rockwell Medical | $1.22
+0.8% | 4/24/2012 | | Initiated Coverage | $176.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 4/24/2012 |
SYK Stryker | $370.59
+1.1% | 4/20/2012 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 4/20/2012 |
PODD Insulet | $309.11
-1.0% | 4/18/2012 | | Upgrade | | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Insulet (NASDAQ:PODD) on 4/18/2012 |
TRS TriMas | $37.71
+0.6% | 3/15/2012 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of TriMas (NASDAQ:TRS) on 3/15/2012 |
OMER Omeros | $4.58
+8.5% | 3/13/2012 | | Boost Price Target | $13.00 ➝ $16.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 3/13/2012 |
AMGN Amgen | $297.89
+0.2% | 3/7/2012 | | Reiterated Rating | $57.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 3/7/2012 |
VSTM Verastem | $8.70
-3.2% | 3/7/2012 | | Initiated Coverage | | Buy ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of Verastem (NASDAQ:VSTM) on 3/7/2012 |
ANIP ANI Pharmaceuticals | $89.64
+0.6% | 2/27/2012 | | Reiterated Rating | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 2/27/2012 |
MDGL Madrigal Pharmaceuticals | $443.01
-1.5% | 2/22/2012 | | Reiterated Rating | $8.00 | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 2/22/2012 |
MGIC Magic Software Enterprises | $20.68
+1.4% | 2/15/2012 | | Boost Price Target | $8.00 ➝ $10.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 2/15/2012 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 2/6/2012 | | Boost Price Target | $19.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/6/2012 |
DAL Delta Air Lines | $57.32
+0.4% | 2/6/2012 | | Reiterated Rating | $14.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 2/6/2012 |
ALGT Allegiant Travel | $62.79
+4.8% | 2/2/2012 | | Boost Price Target | $62.00 | | 00.00% | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 2/2/2012 |
|
POWL Powell Industries | $304.06
-1.1% | 1/26/2012 | | Initiated Coverage | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 1/26/2012 |
SILC Silicom | $17.42
+1.0% | 1/24/2012 | | Boost Price Target | $20.00 ➝ $25.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 1/24/2012 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 1/23/2012 | | Reiterated Rating | $51.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 1/23/2012 |
LUV Southwest Airlines | $32.56
+0.8% | 1/20/2012 | | Reiterated Rating | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 1/20/2012 |
AMGN Amgen | $297.89
+0.2% | 1/17/2012 | | Reiterated Rating | $57.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 1/17/2012 |
MDGL Madrigal Pharmaceuticals | $443.01
-1.5% | 1/5/2012 | | Initiated Coverage | $8.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 1/5/2012 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 1/4/2012 | | Reiterated Rating | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/4/2012 |
WWD Woodward | $257.72
+1.3% | 1/4/2012 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Woodward (NASDAQ:WWD) on 1/4/2012 |
AMGN Amgen | $297.89
+0.2% | 12/23/2011 | | Reiterated Rating | $57.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/23/2011 |
ANIP ANI Pharmaceuticals | $89.64
+0.6% | 12/15/2011 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/15/2011 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 12/13/2011 | | Lower Price Target | $51.00 | | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/13/2011 |
INTC Intel | $36.83
-1.3% | 12/13/2011 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 12/13/2011 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 12/12/2011 | | Reiterated Rating | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/12/2011 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 12/12/2011 | | Reiterated Rating | $52.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/12/2011 |
OMER Omeros | $4.58
+8.5% | 12/5/2011 | | Upgrade | $13.00 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 12/5/2011 |
ROG Rogers | $83.21
+1.2% | 12/2/2011 | | Initiated Coverage | $55.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Rogers (NYSE:ROG) on 12/2/2011 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 12/1/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/1/2011 |
AMGN Amgen | $297.89
+0.2% | 12/1/2011 | | Initiated Coverage | $62.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/1/2011 |
CRIS Curis | $1.65
+2.5% | 11/30/2011 | | Reiterated Rating | $600.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/30/2011 |
AAPL Apple | $258.02
+0.3% | 11/29/2011 | | Reiterated Rating | $16.07 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/29/2011 |
EW Edwards Lifesciences | $77.03
+0.5% | 11/29/2011 | | Reiterated Rating | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/29/2011 |
LUV Southwest Airlines | $32.56
+0.8% | 11/21/2011 | | Reiterated Rating | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 11/21/2011 |
DELL Dell Technologies | $140.64
-4.6% | 11/15/2011 | | Reiterated Rating | $18.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Dell Technologies (NYSE:DELL) on 11/15/2011 |
ADNT Adient | $25.92
+4.3% | 11/11/2011 | | Initiated Coverage | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Adient (NYSE:ADNT) on 11/11/2011 |
EW Edwards Lifesciences | $77.03
+0.5% | 11/11/2011 | | Reiterated Rating | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/11/2011 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 11/10/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/10/2011 |
CRIS Curis | $1.65
+2.5% | 11/10/2011 | | Reiterated Rating | $600.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/10/2011 |
INTC Intel | $36.83
-1.3% | 11/10/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 11/10/2011 |
AAPL Apple | $258.02
+0.3% | 11/9/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/9/2011 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 11/9/2011 | | Reiterated Rating | $52.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 11/9/2011 |
GERN Geron | $1.35
-2.2% | 11/9/2011 | | Lower Price Target | $4.00 | | 00.00% | View details for Rodman & Renshaw rating of Geron (NASDAQ:GERN) on 11/9/2011 |
USEG U.S. Energy | $1.21
| 11/8/2011 | | Reiterated Rating | $47.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of U.S. Energy (NASDAQ:USEG) on 11/8/2011 |
ERII Energy Recovery | $15.77
-0.6% | 11/4/2011 | | Reiterated Rating | | Market Perform | 00.00% | View details for Rodman & Renshaw rating of Energy Recovery (NASDAQ:ERII) on 11/4/2011 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 11/1/2011 | | Reiterated Rating | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/1/2011 |
AUDC AudioCodes | $9.64
-0.8% | 11/1/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of AudioCodes (NASDAQ:AUDC) on 11/1/2011 |
CYTK Cytokinetics | $56.97
+1.2% | 11/1/2011 | | Reiterated Rating | $4.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 11/1/2011 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 10/28/2011 | | Reiterated Rating | $52.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 10/28/2011 |
ALGT Allegiant Travel | $62.79
+4.8% | 10/27/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 10/27/2011 |
CEVA Ceva | $28.02
+0.2% | 10/27/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Ceva (NASDAQ:CEVA) on 10/27/2011 |
JBLU JetBlue Airways | $4.83
+2.8% | 10/27/2011 | | Reiterated Rating | $6.00 | Market Perform | 00.00% | View details for Rodman & Renshaw rating of JetBlue Airways (NASDAQ:JBLU) on 10/27/2011 |
DAL Delta Air Lines | $57.32
+0.4% | 10/26/2011 | | Boost Price Target | $14.00 | | 00.00% | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 10/26/2011 |
ALK Alaska Air Group | $49.09
+0.2% | 10/21/2011 | | Reiterated Rating | $39.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alaska Air Group (NYSE:ALK) on 10/21/2011 |
LUV Southwest Airlines | $32.56
+0.8% | 10/21/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 10/21/2011 |
AAPL Apple | $258.02
+0.3% | 10/19/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 10/19/2011 |
INTC Intel | $36.83
-1.3% | 10/19/2011 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 10/19/2011 |
ALNY Alnylam Pharmaceuticals | $456.35
-1.0% | 10/14/2011 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 10/14/2011 |
BMY Bristol Myers Squibb | $45.39
-0.7% | 10/14/2011 | | Initiated Coverage | $52.50 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 10/14/2011 |
CYTK Cytokinetics | $56.97
+1.2% | 10/13/2011 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 10/13/2011 |
NPO Enpro | $228.50
+0.1% | 10/13/2011 | | Initiated Coverage | $47.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 10/13/2011 |
CEVA Ceva | $28.02
+0.2% | 10/7/2011 | | Reiterated Rating | $36.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Ceva (NASDAQ:CEVA) on 10/7/2011 |
AAPL Apple | $258.02
+0.3% | 10/5/2011 | | Reiterated Rating | $16.07 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 10/5/2011 |
INTC Intel | $36.83
-1.3% | 10/3/2011 | | Reiterated Rating | | Outperform | 00.00% | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 10/3/2011 |
AGEN Agenus | $4.14
+5.1% | 9/26/2011 | | Reiterated Rating | $40.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Agenus (NASDAQ:AGEN) on 9/26/2011 |
SEED Origin Agritech | $1.43
-8.9% | 9/15/2011 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of Origin Agritech (NASDAQ:SEED) on 9/15/2011 |
SILC Silicom | $17.42
+1.0% | 9/8/2011 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 9/8/2011 |
EW Edwards Lifesciences | $77.03
+0.5% | 8/15/2011 | | Upgrade | $11.00 | Underperform ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 8/15/2011 |
EXAS Exact Sciences | $56.72
+0.9% | 8/15/2011 | | Upgrade | $7.00 ➝ $12.00 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Exact Sciences (NASDAQ:EXAS) on 8/15/2011 |
SYK Stryker | $370.59
+1.1% | 8/15/2011 | | Upgrade | $56.00 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 8/15/2011 |
EXAS Exact Sciences | $56.72
+0.9% | 8/3/2011 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Rodman & Renshaw rating of Exact Sciences (NASDAQ:EXAS) on 8/3/2011 |
WOLF Wolfspeed | $24.59
-0.4% | 8/2/2011 | | Upgrade | $5.00 | Market Perform ➝ Outperform | 00.00% | View details for Rodman & Renshaw rating of Wolfspeed (NYSE:WOLF) on 8/2/2011 |
